Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

@article{L2011ImmunotherapyFM,
  title={Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?},
  author={Chen L{\"u} and Andrew J. Williams and Venu Chalasani and Carlos H Martinez and Joseph L. Chin},
  journal={Expert opinion on biological therapy},
  year={2011},
  volume={11 1},
  pages={99-108}
}
IMPORTANCE OF THE FIELD Prostate cancer is the leading malignancy in North American men and despite improvements in treatments 20 - 30% of patients will relapse. Immunotherapy using activated mononuclear cells is a way to harness the body's adaptive immune response to fight metastatic prostate cancer. AREAS COVERED IN THIS REVIEW In 2005, at least 10 therapeutic cancer vaccines, designed to confer active, specific immunotherapy against tumor-associated antigens, were in clinical trials. These… CONTINUE READING